%0 Journal Article
%T Finerenone and diabetic renal disease: a narrative review.
%A Venkatesan K
%A Cheryeth MMJ
%A Verghese AT
%A Mathews AM
%A Ravisankar N
%A Unnikrishnan P
%A Prakash V
%A Harimohan H
%A Haroon NN
%A James S
%A Cherian S
%J Endocrine
%V 0
%N 0
%D 2024 Aug 14
%M 39143421
%F 3.925
%R 10.1007/s12020-024-03945-7
%X Overactivation of mineralocorticoid receptors occurs in cardiorenal diseases. Many patients with type 2 diabetes often progress to chronic kidney disease (CKD) and require dialysis. Finerenone is the first oral non-steroidal mineralocorticoid receptor (MR) antagonist used in patients with diabetic kidney disease and heart failure. Finerenone (also known as Kerendia) is more potent than spironolactone in reducing the progression of CKD and exerts its effect equally on the heart and kidneys, improving cardiovascular outcomes. Research demonstrates that finerenone improves proteinuria and glomerular filtration rate (GFR) if taken alone or in combination with sodium-glucose transporter 2 inhibitors (SGLT2i). Finerenone has been found to decrease mortality in patients with diabetic renal disease and improve quality of life. Its side effects, unlike those of spironolactone, do not include gynecomastia. However, it can result in hyperkalemia, which needs to be monitored. In this narrative review, we aim to investigate the mechanisms of action of finerenone and its implications in patients with type 2 diabetes.